{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:15Z","timestamp":1783075935205,"version":"3.54.6"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/ftd.0b013e31815b3f62","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T02:16:39Z","timestamp":1236219399000},"page":"758-766","source":"Crossref","is-referenced-by-count":38,"title":["Therapeutic Drug Monitoring of Escitalopram in an Outpatient Setting"],"prefix":"10.1097","volume":"29","author":[{"given":"Margareta","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D","family":"Cherm\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01244820","article-title":"The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.","volume":"88","author":"Hyttel","year":"1992","journal-title":"J Neural Transm Gen Sect"},{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/chir.530070602","article-title":"Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC.","volume":"7","author":"Rochat","year":"1995","journal-title":"Chirality"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0028-3908(03)00138-2","article-title":"The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.","volume":"45","author":"Mork","year":"2003","journal-title":"Neuropharmacology"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-004-1865-z","article-title":"Escitalopram versus citalopram: the surprising role of the R-enantiomer.","volume":"174","author":"Sanchez","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000028333","article-title":"Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes.","volume":"59","author":"Olesen","year":"1999","journal-title":"Pharmacology"},{"key":"R6-7-20210129","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00023210-200317050-00004","article-title":"Escitalopram: a review of its use in the management of major depressive and anxiety disorders.","volume":"17","author":"Waugh","year":"2003","journal-title":"CNS Drugs"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/0091270005280860","article-title":"The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.","volume":"45","author":"Sogaard","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R9-7-20210129","first-page":"109","article-title":"Plasma levels of citalopram enantiomers and metabolites in elderly patients.","volume":"33","author":"Foglia","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","article-title":"Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.","volume":"24","author":"Reis","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00007691-200304000-00007","article-title":"Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.","volume":"25","author":"Reis","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.ftd.0000158873.54100.d4","article-title":"Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study.","volume":"27","author":"Reis","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00007691-199506000-00011","article-title":"Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography.","volume":"17","author":"Rochat","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/(SICI)1520-636X(1997)9:7<686::AID-CHIR9>3.0.CO;2-5","article-title":"Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.","volume":"9","author":"Sidhu","year":"1997","journal-title":"Chirality"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00007691-200004000-00014","article-title":"Stereoselective HPLC-assay for citalopram and its metabolites.","volume":"22","author":"Zheng","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00007691-200112000-00011","article-title":"Enantioselective analysis of citalopram and metabolites in adolescents.","volume":"23","author":"Carlsson","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/bmj.283.6286.298","article-title":"Compliance with drug treatment.","volume":"283","author":"OHanrahan","year":"1981","journal-title":"BMJ"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-8510(01)00178-6","article-title":"A review of the literature on the economics of noncompliance. Room for methodological improvement.","volume":"59","author":"Cleemput","year":"2002","journal-title":"Health Policy"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.yic.0000091305.72168.6e","article-title":"Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners.","volume":"18","author":"Akerblad","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"R23-7-20210129","first-page":"443","article-title":"Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations.","volume":"82","author":"Reis","year":"2004","journal-title":"J Affect Disord"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.yic.0000074988.54339.7c","article-title":"Escitalopram (10-20 mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.","volume":"18","author":"Lepola","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0278-5846(82)80181-4","article-title":"Kinetics of citalopram in man; plasma levels in patients.","volume":"6","author":"Fredricson Overo","year":"1982","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00007691-199302000-00002","article-title":"Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.","volume":"15","author":"Sindrup","year":"1993","journal-title":"Ther Drug Monit"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01874.x","article-title":"Metabolism of citalopram enantiomers in CYP2C19\/CYP2D6 phenotyped panels of healthy Swedes.","volume":"56","author":"Herrlin","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","article-title":"Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.","volume":"51","author":"Hagg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00007691-199604000-00001","article-title":"The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method.","volume":"18","author":"Leinonen","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00432209","article-title":"Kinetics of citalopram in elderly patients.","volume":"86","author":"Fredricson Overo","year":"1985","journal-title":"Psychopharmacology"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00007691-200002000-00024","article-title":"Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.","volume":"22","author":"Dahl","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","article-title":"Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?","volume":"22","author":"Rasmussen","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R34-7-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R35-7-20210129","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.clpt.6100188","article-title":"The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.","volume":"81","author":"Sjoqvist","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R36-7-20210129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients.","volume":"101","author":"Lundmark","year":"2000","journal-title":"Acta Psychiatr Scand"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31815b3f62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:35:24Z","timestamp":1620952524000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200712000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31815b3f62","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}